# Safety and Efficacy Study of CC312 for Moderate to Severe SLE

> **NCT07177911** · PHASE1 · RECRUITING · sponsor: **CytoCares Inc** · enrollment: 32 (estimated)

## Conditions studied

- SLE - Systemic Lupus Erythematosus

## Interventions

- **DRUG:** CC312
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07177911
- **Lead sponsor:** CytoCares Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-11
- **Primary completion:** 2027-09-10
- **Final completion:** 2027-09-10
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07177911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07177911, "Safety and Efficacy Study of CC312 for Moderate to Severe SLE". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07177911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*